Long-term data from the phase 3 CARTITUDE-4 trial (NCT04181827) revealed that patients with standard-risk relapsed/refractory multiple myeloma treated with ciltacabtagene autoleucel (cilta-cel; Carvykti) experienced low rates of disease progression, suggesting a potential cure fraction in this patient population. The findings presented at the 2025 ASH Annual Meeting and Exposition showed that in the standard-risk, as-treated patient population from CARTITUDE-4 (n = 59), cilta-cel elicited a 30-month progression-free survival (PFS) rate of 80.5% and a 30-month overall survival (OS) rate of 87.3%. When expanding this population to include patients harboring 1q gains or amplifications (n = 105), the 30-month PFS and OS rates were 71.7% and 86.1%, respectively. Notably, 86% of patients with standard-risk cytogenetics (n = 51/59) were alive and progression-free 1 year after treatment; the respective 30-month PFS and OS rates for this subgroup were 93.1% and 93.7%. Furthermore, 81% of evaluable patients at 1 year (n = 26/32) achieved a minimal residual disease (MRD)–negative complete response (CR). All of these patients remained progression-free at 30 months. Lead study author Luciano Costa, MD, stated that low rates of progression seen in these [standard-risk] patients are indicative of a potential cure fraction, which will be further defined with additional follow-up.
